Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer - PubMed (original) (raw)
Affiliations
- PMID: 16328035
Comparative Study
Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer
Tomonori Yano et al. Oncol Rep. 2006 Jan.
Abstract
A monoclonal antibody to HER2 protein is widely used in the treatment of patients with HER2-overexpressing breast cancer and has also been found to exhibit antitumor activity in human gastric cancer cells that overexpress HER2. The purpose of this study was to evaluate the frequency of HER2 overexpression and concordance between the results for protein expression and gene amplification in both surgical and biopsy specimens of gastric cancer as assessed with two commercial kits, one for immunohistochemistry (IHC) and the other for fluorescence in situ hybridization (FISH). The specimens consisted of formalin-fixed, paraffin-embedded sections of biopsy specimens and surgically resected tumors from 200 cases of invasive gastric cancer that had been treated surgically at the National Cancer Center Hospital East. The lesions were analyzed with the IHC kit, and expression was graded by the United States Food and Drug Administration (FDA)-approved grading system. Gene amplification was evaluated by FISH. IHC revealed HER2 overexpression in 46 of the 200 (23%) cases. The FISH assay was technically successful in 199 cases (99.5%), and gene amplification was observed in 54 cases (27.1%). The concordance rate between the results obtained by IHC and FISH was 86.9%. The concordance rate between the findings in the surgically resected tumors and the 200 pre-treatment biopsy specimens was 88.7%. HER2 expression can be assessed in gastric cancer with a commercial kit as previously reported in breast cancer. Even small biopsy specimens were found to be suitable for evaluating gastric cancer for HER2 overexpression.
Similar articles
- Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study.
Kanta SY, Yamane T, Dobashi Y, Mitsui F, Kono K, Ooi A. Kanta SY, et al. Hum Pathol. 2006 Oct;37(10):1333-43. doi: 10.1016/j.humpath.2006.05.008. Epub 2006 Aug 10. Hum Pathol. 2006. PMID: 16949920 - Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
Kammori M, Kurabayashi R, Kashio M, Sakamoto A, Yoshimoto M, Amano S, Kaminishi M, Yamada T, Takubo K. Kammori M, et al. Oncol Rep. 2008 Mar;19(3):651-6. Oncol Rep. 2008. PMID: 18288397 - HER2 status in breast cancer determined by IHC and FISH: comparison of the results.
Mrozkowiak A, Olszewski WP, Piaścik A, Olszewski WT. Mrozkowiak A, et al. Pol J Pathol. 2004;55(4):165-71. Pol J Pathol. 2004. PMID: 15757204 - Assessment of a HER2 scoring system for gastric cancer: results from a validation study.
Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J, Henkel T. Hofmann M, et al. Histopathology. 2008 Jun;52(7):797-805. doi: 10.1111/j.1365-2559.2008.03028.x. Epub 2008 Apr 18. Histopathology. 2008. PMID: 18422971 - Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines.
Hicks DG, Tubbs RR. Hicks DG, et al. Hum Pathol. 2005 Mar;36(3):250-61. doi: 10.1016/j.humpath.2004.11.010. Hum Pathol. 2005. PMID: 15791569 Review.
Cited by
- Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study.
Shitara K, Yamaguchi K, Muro K, Yasui H, Sakai D, Oshima T, Fujimura M, Sato Y, Yamazaki S, Wakabayashi T, Sugihara M, Kamio T, Shoji H. Shitara K, et al. Int J Clin Oncol. 2024 Jan;29(1):27-35. doi: 10.1007/s10147-023-02422-x. Epub 2023 Nov 14. Int J Clin Oncol. 2024. PMID: 37964066 Free PMC article. - Human epidermal growth factor 2 overexpressed alpha-fetoprotein-producing-gastric cancer.
Shimizu H, Kochi M, Fujii M, Watabe M, Matsuno Y, Kawai T, Suda H, Tanino T, Nakanishi Y, Masuda S, Okamura Y. Shimizu H, et al. Discov Oncol. 2023 Jun 24;14(1):111. doi: 10.1007/s12672-023-00731-1. Discov Oncol. 2023. PMID: 37354221 Free PMC article. - Pharmacovigilance Analysis of Heart Failure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer.
Waliany S, Caswell-Jin J, Riaz F, Myall N, Zhu H, Witteles RM, Neal JW. Waliany S, et al. JACC CardioOncol. 2023 Jan 17;5(1):85-98. doi: 10.1016/j.jaccao.2022.09.007. eCollection 2023 Feb. JACC CardioOncol. 2023. PMID: 36875913 Free PMC article. - Development of the B cell cancer vaccine HER-vaxx for the treatment of her-2 expressing cancers.
Ede NJ, Good AJ, Tobias J, Garner-Spitzer E, Zielinski CC, Wiedermann U. Ede NJ, et al. Front Oncol. 2022 Dec 12;12:939356. doi: 10.3389/fonc.2022.939356. eCollection 2022. Front Oncol. 2022. PMID: 36578947 Free PMC article. Review. - Establishment of gastric cancer organoid and its application in individualized therapy.
Miao X, Wang C, Chai C, Tang H, Hu J, Zhao Z, Luo W, Zhang H, Zhu K, Zhou W, Xu H. Miao X, et al. Oncol Lett. 2022 Oct 26;24(6):447. doi: 10.3892/ol.2022.13567. eCollection 2022 Dec. Oncol Lett. 2022. PMID: 36420067 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous